TLX1N Stock Chart & Stats
$302.55
$0.00(0.00%)
At close: 4:00 PM EDT
$302.55
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$302.55 - $302.55
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$64.84B
Enterprise Value$6.39K
Total Cash (Recent Filing)$363.61M
Total Debt (Recent Filing)$836.98M
Price to Earnings (P/E)109.7
Beta-0.74
Next Earnings
Feb 19, 2027EPS Estimate
-1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding339,894,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio2.81
Price to Book (P/B)6.08
Price to Sales (P/S)3.04
P/FCF Ratio-44.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$313.60Price Target Upside3.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.99
Revenue Forecast (FY)$12.43B
Bulls Say, Bears Say
Bulls Say
Commercial Growth And Market Share GainsSustained double-digit revenue growth and repeated PSMA unit and revenue share gains indicate strong commercial execution and product adoption. This expanding base can support operating leverage, fund pipeline investment, and strengthen Telix’s position in targeted molecular imaging over the coming quarters.
Improving Margins And Operating DisciplineHigher gross margins alongside lower operating expense intensity suggest improving economics as the business scales. If maintained, this combination can convert revenue growth into stronger operating profit, provide greater resilience against reimbursement pressure, and reduce the resources needed to support future expansion.
Pipeline Depth And Commercial InfrastructureAdvancing late-stage programs and broader manufacturing and distribution capabilities create multiple routes to future product expansion beyond the current commercial franchise. The Regeneron collaboration and infrastructure investments may improve development capacity and support more reliable commercialization of targeted therapies.
Bears Say
Rising Leverage Reduces Financial FlexibilityThe faster increase in debt than equity raises financial risk while earnings remain uneven. Higher leverage can constrain investment choices, increase sensitivity to weaker profitability, and leave less flexibility to absorb setbacks or fund the company’s expanding development and infrastructure commitments.
Recent Cash-flow DeteriorationThe reversal from positive to negative operating and free cash flow weakens internal funding capacity and makes execution more dependent on the balance sheet or external financing. This is particularly important as Telix increases R&D and continues investing in manufacturing and pipeline growth.
Zircaix Regulatory SetbackThe CRL creates uncertainty over the timing and resources required to secure approval for Zircaix, delaying potential commercial contribution from the asset. It also highlights execution risk in the regulatory and manufacturing process, which could affect pipeline sequencing and near-term investment priorities.
Telix Pharmaceuticals News
TLX1N FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest stock price was $302.55 and its highest was $302.55 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is $64.84B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Feb 19, 2027 which is in 138 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Aug 19, 2026. The company reported $3.074 earnings per share for the quarter, beating the consensus estimate of $0.362 by $2.712.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is -1.19.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 339,894,000 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of $3.074 in its last earnings report, beating expectations of $0.362. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in MX:TLX1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telix Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$313.60 (3.65% Upside)
$313.60 (3.65% Upside)
Blogger Sentiment
Bullish
MX:TLX1N Sentiment 97%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.45%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
TLX1N Company Deck
TLX1N Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple strong commercial and clinical positives: double‑digit revenue growth (H1 revenue $477M, +22% YoY), robust Precision Medicine momentum (~$390M, +27% YoY), improving margins, a solid cash position ($252M), near-term regulatory catalysts (Pixclara PDUFA on 11 Sep) and advancement of Phase III therapeutic programs and the BiPASS study. Offsetting these are material regulatory uncertainties (notably the Zircaix CRL and required resubmission to address third‑party manufacturing deficiencies), timing risk for European approvals, higher near‑term R&D spend ($230M–$270M guidance) and competitive/reimbursement dynamics. Overall, the highlights — including strong commercial execution, product launches, pipeline progress and strategic partnerships — materially outweigh the lowlights, though execution against regulatory milestones and funding of increased R&D spend remain key watch items.View all MX:TLX1N earnings summariesTLX1N Stock 12 Month Forecast
Average Price Target
$313.60
▲(3.65% Upside)